> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Contaminated Atovaquone Recalled by Bionpharma
- URL: https://www.fdaweb.com/contaminated-atovaquone-recalled-by-bionpharma/
- Published: 2024-09-19T12:00:00.000Z
- Updated: 2026-09-14T14:41:49.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157820

Bionpharma has recalled (Class 1) a single Batch (#2310083) of atovaquone oral suspension, 750mg per mL, due to contamination with *Cohnella* bacteria. The product was manufactured by CoreRx in Clearwater, FL and distributed by Bionpharma, a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bionpharma-inc-issues-voluntary-nationwide-recall-atovaquone-oral-suspension-due-bacterial?utm%5Fmedium=email&utm%5Fsource=govdelivery) says. The quinone antimicrobial drug is indicated for preventing *pneumocycstis jirovecii* pneumonia in adults and adolescents aged 13 and older.

“In the population most at risk, immunocompromised population, there is a reasonable probability that microbial contamination of atovaquone oral suspension can result in disseminated, life-threatening infections such as inflammation of the heart and permanent damage to soft tissue,” the notice says. To date, Bionpharma has not received adverse event reports related to the issue.